Skyrizi

Drug Overview

Skyrizi is a highly advanced prescription medication widely utilized within the field of Dermatology to treat chronic, severe skin inflammation. It belongs to a specialized class of medications known as Interleukin-23 (IL-23) inhibitors. As a modern Biologic medication, Skyrizi is prescribed for patients whose skin conditions have not adequately responded to traditional topical treatments or standard systemic pills.

Because it is engineered from living cells rather than synthesized from simple chemicals, it acts as a highly precise Targeted Therapy. Skyrizi works by neutralizing a specific inflammatory signal in the body, halting the disease at its source with a convenient dosing schedule of just four maintenance injections a year.

Key Drug Information:

• Generic Name: Risankizumab (or risankizumab-rzaa)
• US Brand Name: Skyrizi
• Drug Category: Dermatology
• Drug Class: Interleukin-23 (IL-23) Inhibitor / Monoclonal Antibody
• Route of Administration: Subcutaneous (under the skin) injection
• FDA Approval Status: Fully FDA-approved

What Is It and How Does It Work? (Mechanism of Action)

Skyrizi (risankizumab) is an advanced Biologic and Immunotherapy designed to treat autoimmune conditions by acting on highly specific molecular targets within the immune system.

To understand how this drug works, it is important to understand the root cause of plaque psoriasis. In a healthy immune system, proteins known as cytokines help coordinate the body’s defense against infections. However, in people with psoriasis, the immune system overproduces a specific cytokine called Interleukin-23 (IL-23). IL-23 acts as a master switch; it signals the body to activate a specific inflammatory pathway (the Th17 pathway). This pathway continuously commands the skin cells (keratinocytes) to multiply at an abnormally fast rate. This hyperactive growth causes skin cells to pile up rapidly, forming thick, red, scaly, and itchy plaques.

Skyrizi acts as a Smart Drug by specifically hunting down and binding to the “p19 subunit” of the IL-23 protein. By attaching to this exact structural piece, Skyrizi neutralizes IL-23 and prevents it from connecting with its corresponding receptors on the immune cells. By chemically blocking this connection at the molecular level, Skyrizi shuts down the inflammatory cascade at its source. This halts the abnormal overproduction of skin cells, allowing the thick plaques to flatten, clear, and heal.

FDA-Approved Clinical Indications

Primary Indication

• Moderate to Severe Psoriasis: Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Other Approved Uses

Oncological Indications

• None currently approved. (Skyrizi is an immunomodulator used strictly for autoimmune and inflammatory conditions, not for cancer treatment).

Non-Oncological Indications

• Psoriatic Arthritis: Treatment of active psoriatic arthritis in adults.
• Crohn’s Disease: Treatment of moderately to severely active Crohn’s disease in adults.
• Ulcerative Colitis: Treatment of moderately to severely active ulcerative colitis in adults.

Dosage and Administration Protocols

For dermatology patients, Skyrizi is administered via a subcutaneous injection (an injection into the fatty tissue just beneath the skin). It is available as a single-dose prefilled syringe or a single-dose prefilled autoinjector pen.

Special Population Adjustments

• Renal and Hepatic Insufficiency: No specific dosage adjustments are required for patients with mild, moderate, or severe kidney or liver impairment, as monoclonal antibodies are typically cleared through natural protein degradation pathways rather than through renal or hepatic metabolism.
• Pediatrics: Skyrizi is currently only approved for adult patients (18 years of age and older).

Clinical Efficacy and Research Results

Skyrizi is highly regarded within the dermatological community for its rapid, deep, and long-lasting clearance of psoriasis plaques. Clinical success is frequently measured by the PASI score (Psoriasis Area and Severity Index).

Based on landmark clinical trials (such as ultIMMa-1 and ultIMMa-2) and long-term research extensions (2020–2026), Skyrizi has demonstrated the following efficacy profile as a premier Biologic:

• Superior Clearance: Approximately 75% of patients taking Skyrizi achieve a PASI 90 (a 90% improvement in skin clearance) within the first 16 weeks of treatment.
• Complete Clearance: Roughly 50% to 60% of patients achieve a PASI 100 (100% completely clear skin) by week 16.
• Long-Term Durability: Long-term extension data extending up to 5 years show that over 85% of patients who achieve clear or almost clear skin maintain that high level of response consistently through five full years of continuous, quarterly treatment.
• Joint Benefits: For patients with comorbid psoriatic arthritis, Skyrizi significantly reduces joint pain, swelling, and morning stiffness, while improving overall physical function.

Safety Profile and Side Effects

Note: There is currently no FDA Black Box Warning for Skyrizi (risankizumab).

Because Skyrizi alters the immune system by dampening the IL-23 pathway, it can slightly lower the body’s natural ability to fight off certain infections.

Common Side Effects (>10%)

• Upper Respiratory Infections: Such as the common cold, sinus infections, or sore throats.
• Headaches: Mild to moderate headaches.
• Fatigue: A general feeling of tiredness.
• Injection Site Reactions: Mild redness, pain, itching, or swelling where the injection was given.
• Tinea Infections: Mild fungal infections, such as ringworm or athlete’s foot.

Serious Adverse Events

• Serious Infections: An increased risk of bacterial, viral, or fungal infections that may require medical treatment or hospitalization. Tuberculosis (TB) reactivation is a potential risk.
• Hypersensitivity Reactions: Severe allergic reactions, including anaphylaxis or severe rash, though very uncommon.
• Hepatotoxicity: Drug-induced liver injury has been reported, predominantly during the high-dose intravenous induction phase used for Crohn’s disease and Ulcerative Colitis, though it is rare in psoriasis patients.

Management Strategies

• If a patient develops a serious or chronic infection, Skyrizi therapy should be paused until the infection is completely resolved under a doctor’s care.
• Seek immediate emergency medical care if signs of a severe allergic reaction occur (e.g., trouble breathing, swelling of the face, lips, tongue, or throat).

Connection to Stem Cell and Regenerative Medicine (Research Areas)

While Skyrizi is actively used as a highly specific Targeted Therapy to control active disease, emerging research (2020-2026) is investigating the role of the IL-23 pathway in chronic tissue damage and regeneration. In severe plaque psoriasis, the continuous inflammatory “cytokine storm” disrupts the normal life cycle of the skin’s basal stem cells, forcing them to divide improperly and preventing the skin from forming a healthy, protective barrier. Researchers are exploring how neutralizing the IL-23 pathway with a Smart Drug like Skyrizi stabilizes the cellular microenvironment. Calming this ambient inflammation provides the skin’s native epidermal stem cells the biological “quiet time” they need to differentiate normally, thereby allowing the body to regenerate a fully healthy, properly structured epidermis without the need for external cellular implants.

Patient Management and Practical Recommendations

Pre-Treatment Tests

Before a patient can begin taking Skyrizi, their healthcare provider will require:

• Tuberculosis (TB) Testing: A blood test (such as a QuantiFERON gold test) or a skin test to rule out active or latent (hidden) TB.
• Baseline Blood Work: Standard liver enzyme tests (LFTs) and a complete blood count (CBC) to establish a baseline of general organ health.

Precautions During Treatment

• Live Vaccines: Patients must avoid live-attenuated vaccines (such as the MMR, yellow fever, or the nasal flu spray) while on Skyrizi. Non-live, inactivated vaccines (like the standard injectable flu shot) are generally safe and recommended.
• Infection Vigilance: Patients should monitor themselves closely for signs of infection, such as persistent fever, chills, a cough that will not go away, or burning during urination, and report them to their physician promptly.

Do’s and Don’ts

• DO store Skyrizi in the refrigerator (2°C to 8°C / 36°F to 46°F) and keep it in its original carton to protect it from light.
• DO take the medication out of the refrigerator 30 to 45 minutes before your injection to allow it to reach room temperature naturally (this significantly reduces injection pain).
• DO rotate your injection sites among the front of the thighs or the lower stomach (staying at least 2 inches away from the belly button).
• DON’T freeze Skyrizi or use the syringe/pen if it has been previously frozen.
• DON’T shake the syringe or autoinjector pen.
• DON’T inject the medication into areas where the skin is bruised, tender, red, hard, or actively covered by psoriasis plaques.

Legal Disclaimer

The information provided in this guide is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider or specialist physician with any questions you may have regarding a medical condition, medication, or treatment plan. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.